HIV and reproductive care by V. Savasi & E. Ferrazzi
At the beginning of the AIDS epidemic, because of the poor prognosis
of those infected with the disease, couples with an HIV-infected
partner were discouraged from planning a pregnancy. AIDS remains a
serious condition worldwide, with continuing mortality. Even in
industrial countries where efficient and innovative treatments are
available, HIV infection remains a chronic disease with high
morbidity.1 nevertheless, due to antiretroviral therapies, life
expectancy and quality of life of many seropositive patients have
dramatically improved over the last 10 years and many couples with
an HIV-positive partner can consider pregnancy planning.2–4
Assisted reproductive technology (ART) reduces the risk of
contaminating the uninfected partner and helps couples conceive.2,5,6
Furthermore, in recent years the vertical transmission (the risk of
infecting the newborn baby) has drastically decreased (to less than
2%) due to the ability to reach undetectable maternal viral loads
during pregnancy, the liberal use of Caesarean section and restricted
breastfeeding.7 Finally, certain authors have observed that pregnancy
does not worsen the progression of HIV infection or its immunological
parameters.8,9 The American Society for Reproductive Medicine
Committee on Ethics10 and the International Federation of Gynecology
and Obstetrics (FIGO)11 guidelines concerning assisted reproduction in
people infected by HIV have been modified to allow assisted
reproduction in HIV-discordant couples.
The paper from FIGO11 reported that access to antiretroviral drugs and
ART for populations suffering from HIV or for seropositive patients
must be promoted on an equitable basis, and that any restriction on
access to assisted reproduction should be clearly justified and not
based on discrimination. 
Women, including sex workers, have the right to make choices about
their sexual behaviour. Public information and access to the means to
prevent HIV transmission for women and men at all stages of their
reproductive lives are of utmost importance and need to be a concern
for all member organisations and individual practitioners. Seropositive
healthcare providers have an obligation to ensure that they engage in
no behaviour that puts patients at risk. Prevention – by providing
information about high-risk behaviour – is essential. The need for
patients to behave responsibly to avoid spreading the virus, including
the necessity of accepting antiretroviral treatment during pregnancy,
must be highlighted. 
Finally, FIGO suggested that it is essential to offer appropriate advice
to women and men with HIV or whose partners are HIV-positive who
wish to reproduce so that their health, the health of their partner and
that of any future child is protected. Treatment of seropositive couples
by assisted reproductive means that reduce the chance of the woman
and her offspring being exposed to HIV are of proven efficiency. 
It is therefore ethical to offer such techniques in appropriate cases.
Two different medical aspects are analysed in this paper:
reproductive assistance in a discordant couple with male positivity
and in a discordant couple with female positivity.
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Abstract
Three-quarters of individuals infected with HIV are in their reproductive years and can expect an almost normal life expectancy under
antiretroviral treatment. Men and women with HIV face the possibility of viral transmission to their partner or offspring if they want to have a
child by way of spontaneous conception. When only the man is infected, spermatozoa can be isolated from seminal plasma and leukocytes
containing cell-free and cell-associated HIV. After processing, the spermatozoa must be tested for residual contamination and, when negative,
can be used for intrauterine transfer or in vitro fertilisation (IVF) embryo transfer/intracytoplasmatic sperm injection (ICSI). In women with HIV,
self-insemination might be indicated when the couple is fertile or IVF embryo transfer/ICSI when there are infertility problems. Pregnancy should
be planned to minimise the risk of drug-induced toxicity for the conceptus while reducing the vertical transmission rate to a minimum. Elective
Caesarean birth is the recommended mode of delivery and breastfeeding is contraindicated.
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Reproductive Assistance in an HIV-discordant
Couple with an HIV-positive Male 
HIV in Semen
Araneta12 and Matz13 reported that semen used for donor artificial
inseminations can transmit HIV-1 infection. Studies on the presence
of HIV in sperm have also yielded contradictory results. Using
different approaches, Baccetti14 detected HIV-1 particles and HIV-1
DnA in the ejaculated sperm of HIV-seropositive patients. The same
group identified a specific HIV receptor, alternative to CD4+, on the
sperm membrane: this molecule is a galactosyl–alkyl–acyl glycerol
(GalAAG), a glycolipid structurally related to galactosylceramide, the
receptor for HIV identified in CD4+ cells.14,15
At the same time, other authors emphasised the total absence of HIV
particles and nucleic acids in sperm.16–18 They demonstrated that the
separation of seminal fluid and cellular elements from sperm by
washing techniques reduces the viral load of semen detected 
by polymerase chain reaction (PCR) and reverse transcriptase 
PCR. Semprini et al.19 were the first to use washed sperm from 
HIV-1-infected men for intrauterine inseminations (IUI). There are
several reports indicating that HIV-1 DnA cannot be found in washed
spermatozoa isolated from non-spermatozoa seminal cells and
seminal plasma.4,17,20
In contrast to this reassuring epidemiological and laboratory
background, there are reports using  transmission electronic
microscopy that indicate the possibility that HIV-1 virions are
attached to the sperm cell surface and even within its cytoplasm.
Other papers using extraction PCR and in situ PCR, respectively,
report that proviral HIV-1 DnA can be detected in the spermatozoa of
men with AIDS and men infected with HIV-1.14,21–36
To investigate these contradictory findings and assess the role of
sperm-washing techniques in eliminating both HIV-1 RnA and DnA
from semen infected with HIV-1, the authors tested the ejaculate 
of men infected with HIV-1 before and after processing semen.
Testing of the three main seminal fractions – non-spermatozoa cells,
cell-free seminal plasma and spermatozoa – was by highly sensitive
extractive-nested PCR and in situ PCR. All samples of spermatozoa
recovered after separation by gradient centrifugation and swim-up
(sperm washing) were free of HIV-1 RnA above a threshold of 
50 copies/ml and free of proviral DnA. This confirms the findings of
previous reports in which nested PCR4,37,38 was used to assess the
validity of sperm washing in HIV-infected semen. 
Although other more recent methodologies of sperm washing39
confirm the validity of the general principle of removing the cellular
component of semen, contradictory reports could be due to the
inaccuracy of PCR techniques in older studies,40 too low a threshold
(one viral copy) of the PCR assay used to detect viral copies38,41,42 and
improper use of the definition of sperm washing,43 without the final
swim-up of spermatozoa. 
In the authors’ data of seven seminal plasma samples testing
positive for HIV-1 RnA, six were from patients on  highly active
antiretroviral therapies (HAART). Four men had an elevated blood
viral load and three an undetectable viraemia. These results confirm
the findings of previous reports demonstrating discrepancies
between haematic and seminal HIV-1 concentrations,4,44 either due to
a subtherapeutic concentration of antiretroviral drugs in the male
seminal tract or due to production of HIV-1 RnA from localised cells
that respond poorly to treatment. 
The false-positive detection of HIV-1 DnA by in situ PCR in the
semen of HIV-1-non-infected men confirms that this technique is
inadequate for studying the presence of provirus in semen
fractions. The presence of the virus in spermatozoa pellet samples
could be due to the presence of non-sperm cells (nSCs) not
completely eliminated during semen separation by discontinuous
gradient centrifugation before swim-up. Alternatively, these could
be real false-positive results due to non-specific hybridisation of 
in situ PCR. Bagasra,23 nuovo34 and Muciaccia35 showed the presence
of provirus by in situ PCR in spermatozoa and germ cells at all
stages of differentiation, from spermatogonium to round spermatidi.
However, none of these studies assessed proper standards for 
in situ PCR specificity in uninfected males. These methodological
limitations of in situ PCR probably explain why this technique has
been abandoned in recent works. nevertheless, Muciaccia45 in his
study reported the presence of HIV-1 DnA in small amounts of
ejaculated abnormal spermatozoa from HIV-1-infected subjects.
Interestingly, in these subjects a high percentage (58–80%) of
ejaculated spermatozoa had abnormal morphologies and the
percentage of spermatozoa with fragmented DnA (9.5–35.4%)
greatly exceeded normal values (0.9–4.4%). The authors hold that 
in situ PCR, when correctly performed along with positive and
negative controls, is a powerful, highly reliable technique for the
detection of viral DnA in human tissue sections and cells. 
Semen Processing 
In order to eliminate the cell infected by HIV-1 in sperm, we perform
sperm washing. The first report of this technique was published in The
Lancet in 1987.19 We reported a simple method to process the semen
of men infected with HIV to eliminate infected seminal leukocytes 
from the ejaculate in order to recover uninfected spermatozoa 
for intrauterine transfer into HIV-uninfected women. Semen analysis 
was performed and samples were processed using a 40–80% density
gradient (PureCeption kit) to separate motile spermatozoa from 
non-sperm cells, immotile spermatozoa and seminal plasma. The
ejaculate was layered over the gradient and centrifuged at 400g for 30
minutes. After centrifugation, the supernatant was removed and the
sperm pellet recovered and re-suspended in 3ml of fresh medium
(Sage’s Sperm Washing Medium). Washing at 400g for 10 minutes was
performed and the supernatant was discarded. Subsequently, 1ml of
medium was gently layered on the pellet and the tube was incubated
at 37°C for one hour. After swim-up, a supernatant volume of about
500μl was recovered and an aliquot of this volume (100μl) was tested
for detectable HIV-1 RnA using a realtime PCR assay (Biomerieux)
according to the manufacturer’s instructions. The remaining washed
sperm (400μl) was stored at 4°C for about 22 hours and used for IUI
with in vitro fertilisation (IVF) embryo transfer/intracytoplasmatic sperm
injection (IVFET/ICSI) procedures if the PCR test for HIV-1 was negative.
Assisted Reproduction 
The ART programme was offered to serodiscordant couples where
the man was HIV-positive and seeking medical assistance.46 Inclusion
criteria were adopted to protect not only the couple but the possible
child as well: partners were to engage only in protected sexual
relations. HIV status had to be monitored and/or treated and 
long-term compliance had to be assessed by the infectious disease
physician. Standard laboratory criteria were adopted: 
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•   CD4+ lymphocytes >200/mm3 at least twice in the four months
prior to treatment;
•   stable viral load; and
•   infection by an quantifiable, amplifiable strain of HIV-1. 
Each couple was interviewed by a psychologist at inclusion and
thereafter whenever necessary. Female fertility was assessed by
standard procedures. 
In clinical practice it is important to screen HIV-discordant couples
to determine infertility factors due to the high prevalence of
subfertility factors. One of the most important factors is genital
tract infection in both males and females. The exact mechanisms
involved in male-to-female transmission of HIV-1 are as yet
undefined, but circumstantial evidence indicates that genital tract
infections may act as facilitating factors. In sub-Saharan and latin
American countries, where heterosexual transfer of the virus is 
the leading cause of infection, there is also a high prevalence of
genital infection carriers. The presence of a sexually transmitted
pathogen recruits inflammatory cells in both the male and female
genital tract. This may increase the number of HIV-1-infected cells
in the semen or vaginal fluid of the seropositive subject, leading to
a higher risk of infection for the seronegative partner. Conversely,
when genital tract infection is present in the seronegative partner,
the uninfected inflammatory cells may become a specific target 
for the virus. 
The ART laboratory used for the procedure was considered to be a
‘viral risk’ area. It was separated from laboratory facilities used for
couples negative for HIV and hepatitis B and C. The ART laboratory
complied with standard recommended safety precautions. Specific
precautions were implemented against the risk of HIV and hepatitis B
and C contamination, as recommended by the French decree of 10
May 2001.45 The potentially infected gametes and embryos were
handled separately. A special biosafety cabinet workstation was used
for all tasks that involved handling of sperm, oocytes and embryos. 
In the Department of Obstetrics and Gynecology at the luigi Sacco
Biomedical Institute, the IUI pregnancy rate per cycle is 19% and per
couple is 78%. Here, the pregnancy rate per couple was higher than
the average 57% overall pregnancy rate by IUI in serodiscordant
couples summarised by Sauer in 2005.47 These results could be
explained by the routine adoption of ovulation induction with low
doses of recombinant fluorescence in situ hybridisation (FISH) and
timing of ovulation with recombinant luteinising hormone (lH),
according to Marina.40 It could also be due to the standard usage of
fresh sperm after realtime PCR or due to a good selection of cases,
with an average of four attempts per couple. In addition, other
centres used frozen semen.37 There is a negative impact on the
number of available motile sperm after freezing, as already
reported,43 which has a resultant impact on pregnancy rate per IUI. 
At the centre at the luigi Sacco Biomedical Institute more than 3,000
IUIs have been performed. This large number of cases, with safe
pregnancy after sperm washing and the consistent biological results
that have been published, has led the authors to consider the
efficiency of sperm washing to be high.47
The efficiency of IUI, its safe outcome after sperm washing with 
swim-up and its relatively low cost make this first-level procedure the
technique of choice in serodiscordant couples with an HIV-positive
male partner when no other infertility problems are involved. When
the female partner was suffering from infertility factors, the male
partner had fewer than 1x106 total motile cells in the final fraction
after sperm washing or both partners had a combination of
subfertility conditions, IVF/ICSI was performed. The pregnancy rate
per embryo transfer was in agreement with similar smaller HIV
series37 and larger non-HIV series.48 Other markers of outcome were
as good in these couples treated after sperm washing as in other
infertility series of comparable age: fertilisation rate was 65% by IVF
and 88% by ICSI.38
The problem with ICSI in serodiscordant couples is the high multiple
pregnancy rate and possible obstetric and neonatal complications
associated with these pregnancies (14% for Garrido38 and 57.1% for
Pena).48 The possible additional costs determined by pre-natal and
neonatal care in multiple pregnancies should be considered.49–51
In the authors’ experience, the multiple pregnancy rate by IVF/ICSI
was 10%, reflecting the special care in superovulation induction and
embryo transfer. In 2002, at the  luigi Sacco Biomedical Institute,
more than 4,000 IUIs were performed in serodiscordant couples 
and 1,000 fertilisation in vitro and embryo transfer (FIVET)/
ICSI cycles without HIV-1 transmission to the female partners with an
adequate follow up.
Reproductive Assistance in an HIV-discordant
Couple with an HIV-positive Female 
Some preliminary studies suggest that HIV-infected women may
have a decreased fertility rate52 and a higher frequency of
menstruation disturbances associated with low CD4 cell counts53
and upper genital tract infections.54 In addition, severe ovarian
dysfunction, such as premature ovarian failure or ovarian resistance
to stimulation, has also been described.55,56 Ovarian resistance to
hyperstimulation may add to this effect because a greater number of
units of gonadotrophins were needed to adequately stimulate these
patients. This resistance may reflect an underlying subclinical
(normal menses) and subanalytical (comparable basal FISH values)
hypogonadism. Superovulation may be considered a functional
stress test on the ovary.
Very few data are available on the presence of viral material in the
cumulus oophorus complex of infected women. Baccetti26 exposed
unfertilised human oocytes partly surrounded by follicular cells to low
doses of HIV-1 and found that they remained negative for the
presence of HIV-1 DnA. This suggests the resistance of oocytes to
HIV-1 penetration, possibly as a result of the absence of specific
receptors for the virus, as assessed by immunocytochemistry.
Bertrand57 was unable to detect the presence of HIV-1 genetic
material in the follicular fluid or flush fluids of patients with
undetectable plasma viral loads. nevertheless, in one of his patients
with a low but detectable load, HIV-1 RnA was detected in one
follicular fluid and one flush.
A paper from Martinet58 evaluates the ovarian response to IVF
stimulation of HIV-positive patients compared with control patients.
no significant difference was observed between HIV-positive patients
and matched negative controls in terms of ovarian response to
stimulation. The pregnancy rate calculated per transfer was 14%,
which is lower than that obtained by Ohl (23.9%)59 but similar to the
results of Terriou and colleagues (16.1%).60 The latter authors
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performed ICSI and IVF in a series of 29 seropositive women (66
cycles). They compared their results with an age-matched group of
uninfected women and with their overall uninfected population.
Higher cancellation rates and lower pregnancy rates were observed
when the overall population was considered, but these differences
disappeared when using an age-matched group. 
Coll et al.61 also found a clinical pregnancy rate of 16.2% among
infected patients (n=50), which was half that of a group of age-matched
uninfected patients (37.5%). When they restricted their analysis to
cycles with oocyte donation, these differences disappeared (36 versus
44% of patients). These authors therefore concluded that poor IVF
results in HIV-positive women may be due to reduced ovarian
response. Ovarian resistance to hyperstimulation may be involved in
this effect because a greater number of units of gonadotrophins were
needed to adequately stimulate these patients. As stated before, this
resistance may reflect underlying subclinical and subanalytical
hypogonadism and superovulation may be a useful functional stress
test on the ovary. 
Finally, Guibert et al.62 observed increased FSH levels on the third day of
the cycle in a population of 80 HIV-positive patients compared with a
control group of similar age (n=70), and concluded that HIV infection
accelerates ovarian reserve depletion. On the other hand, when
selecting women below 42 years of age with normal basal FISH and
inhibin levels, no difference in ovarian response was observed between
HIV-positive and HIV-negative patients (n=14 for each group). The
authors  at the luigi Sacco Biomedical Institute concluded from these
results that IVF is not influenced by HIV infection in patients with a
normal ovarian reserve. The discrepancies in the results between
studies may be explained by heterogeneities in the populations studied.
Differences in the matching processes and lack of power of the various
studies are other possible explanations. 
Pelvic inflammatory disease has been shown to reduce ovarian
stimulation due to direct damage to the ovaries, follicle loss or
mechanical alterations in follicle development. This may result from
adherences or a deficiency in ovarian vascularisation.63,64 For instance,
a significantly higher prevalence of serum immunoglobulin G (IgG)
antibodies to Chlamydia trachomatis was observed in poor
responders, suggesting a possible detrimental effect of C. trachomatis
on subsequent ovarian function.64 This may explain a tendency
towards reduced ovarian response among HIV-positive patients.
Conclusion
Reproductive counselling for individuals with HIV might motivate
them to ask for reproductive care in order to limit the risk of infecting
uninfected partners, or of superinfection if the partner is also
infected. By offering reproductive care to men infected with HIV, it is
possible to strengthen the message that, by protecting their partners
from becoming infected through unprotected sex, they could in the
future become the healthy mother of an uninfected child. For
uninfected women with an infected partner, the optimal solution
remains protecting themselves from becoming infected to avoid
perinatal transmission of HIV. For women who are HIV-1-positive, the
problem remains the risk of vertical transmission. Significant progress
has been made in this area, but additional research into the
mechanisms of vertical transmission of HIV is still needed. n
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